ATMI Invests in Medinstill Sterile Fill Tech

ATMI invests in Medinstill
ATMI invests in Medinstill

Related tags Investment

Single-use biopharma provider ATMI has invested in sterile connector and fill technology developed by Medical Instill Technologies.

The amount of the investment was not disclosed. The technologies are meant for sterile filling, sterile multiple-dose dispensing, sterile transfer, and packaging sterilization solutions.

The synergy between our INTACT Closed Transfer Systems and disposable technologies from ATMI allows us together to quickly install turn-key fill finish lines, bringing many benefits to a large number of manufacturers​,” Daniel Py, MD, Sc.D., Chairman of Medinstill, said.

The INTACT technology also offers “a means to rapidly reduce drug shortages while overcoming the difficulties associated with installing and running aseptic lines in emerging markets, such as access to specially trained personnel, all at a fraction of the cost of traditional aseptic filling lines​,” Dr. Py added.

ATMI declined to provide any additional information on the investment.

Related news

Show more

Related products

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...